Document is current
Any future updates will be listed below
-
Authors
Correll, Christoph U. http://orcid.org/0000-0002-7254-5646
Koblan, Kenneth S.
Hopkins, Seth C.
Li, Yan
Heather Dworak,
Goldman, Robert
Loebel, Antony
-
Funding
Funding for this research was provided by:
Sunovion (None, None, None, None, None, None, None)
- License Information
-
More Information
Article History
Received: 7 July 2021
Accepted: 3 November 2021
First Online: 9 December 2021
Competing interests
: Dr. Correll has been a consultant and/or advisor to or have received honoraria from Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma. Drs. Koblan, Hopkins, Li, Dworak, Goldman, and Loebel are employees of Sunovion Pharmaceuticals Inc. Medical writing support was provided by Edward Schweizer, MD of Paladin Consulting Group, and was funded by Sunovion Pharmaceuticals Inc.
